Cargando…
Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
PURPOSE: Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evalu...
Autores principales: | Seo, Yu Bin, Choi, Won Suk, Lee, Jacob, Song, Joon Young, Cheong, Hee Jin, Kim, Woo Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292355/ https://www.ncbi.nlm.nih.gov/pubmed/28168172 http://dx.doi.org/10.7774/cevr.2017.6.1.38 |
Ejemplares similares
-
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015) -
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023) -
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022) -
P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023) -
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)